Verition Fund Management LLC Cullinan Oncology, Inc. Transaction History
Verition Fund Management LLC
- $20.3 Billion
- Q2 2025
A detailed history of Verition Fund Management LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 139,660 shares of CGEM stock, worth $955,274. This represents 0.01% of its overall portfolio holdings.
Number of Shares
139,660
Previous 29,175
378.7%
Holding current value
$955,274
Previous $220,000
377.73%
% of portfolio
0.01%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CGEM
# of Institutions
153Shares Held
66.5MCall Options Held
10.6KPut Options Held
917K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$52.3 Million11.28% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$39.3 Million1.7% of portfolio
-
Lynx1 Capital Management LP San Juan, PR4.4MShares$30.1 Million9.81% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$26.4 Million0.67% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$24.3 Million0.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $312M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...